Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Zingo Generic Name & Formulations
Legal Class
Rx
General Description
Lidocaine HCl (as monohydrate) 0.5mg/device; pwd for intradermal inj.
Pharmacological Class
Local anesthetic (amide-type).
How Supplied
Single-use device (disposable, needle-free)—12
Manufacturer
Generic Availability
NO
Zingo Indications
Indications
To provide local analgesia prior to venipuncture in adults and children or peripheral IV cannulation in children.
Zingo Dosage and Administration
Adults and Children
<3yrs: not established. ≥3yrs: Use only on intact skin. Apply one 0.5mg dose to the planned procedure site 1–3 mins before needle insertion; may repeat once at new site after initial attempt failed. Multiple administrations to same site: not recommended.
Zingo Contraindications
Not Applicable
Zingo Boxed Warnings
Not Applicable
Zingo Warnings/Precautions
Warnings/Precautions
Avoid eyes, body orifices, mucous membranes or areas with a compromised skin barrier. Severe hepatic disease or pseudocholinesterase deficiency. Bleeding tendencies or platelet disorders: higher risk of superficial dermal bleeding. Risk of methemoglobinemia (esp. in G6PD deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, infants <6 months of age, concurrent exposure to oxidizing agents or metabolites); monitor. Labor & delivery. Pregnancy (Cat.B). Nursing mothers.
Zingo Pharmacokinetics
See Literature
Zingo Interactions
Interactions
Increased risk of methemoglobinemia when concurrently exposed to nitrates/nitrites, local anesthetics, antineoplastic agents, antibiotics, antimalarials, anticonvulsants, others.
Zingo Adverse Reactions
Adverse Reactions
Application-site reactions (eg, erythema, petechiae, edema, pruritus), systemic reactions (eg, nausea, vomiting), dizziness.
Zingo Clinical Trials
See Literature
Zingo Note
Not Applicable
Zingo Patient Counseling
See Literature
Images
